BG-C477 (CEA ADC)

Disclaimer: This fact sheet is intended for media professionals only.
BG-C477 is an investigational drug for which safety and efficacy have not been established.

WHAT IS BG-C477?

BG-C477, BeOne Medicines first internally discovered antibody-drug conjugate (ADC) to achieve proof-of-concept, is an investigational molecule designed to target carcinoembryonic antigen, or CEA, a protein found at high levels on several types of cancer cells.

THE TARGET: CEA

CEA, also known as CEACAM5, is highly expressed in several epithelial cancers or carcinomas, including certain types of gastrointestinal and lung cancers. Because many cancer cells display CEA on their surface, it may serve as a useful target for antibody drug conjugates (ADCs).

HOW DOES BG-C477 WORK?


BG-C477 is designed to work as a targeted delivery system.

An ADC has three main components:

ANTIBODY
The antibody recognizes and attaches to CEA on the surface of cancer cells.

CONJUGATOR – LINKER
The conjugator-linker system connects the antibody to the cancer-killing payload and is designed to remain stable while traveling through the bloodstream.

PAYLOAD
The payload is a potent anti-cancer medicine that is released after BG-C477 enters the cancer cell.



When BG-C477 binds to a CEA-positive cancer cell, it enters the cell.
The payload is then released, helping damage and destroy the cancer cell.

DIFFERENTIATION: TARGETED DELIVERY TO CEA-POSITIVE TUMORS

Traditional chemotherapy travels throughout the body and can affect both cancer cells and healthy cells.

BG-C477 was designed to deliver a potent payload more selectively to tumor cells expressing CEA.

CEA TARGETING	POTENT ANTI-CANCER PAYLOAD	UNIQUE CONJUGATOR-LINKER DESIGN
The antibody is designed to specifically recognize CEA, helping guide the treatment toward cancer cells.	**BG-C477 carries a highly active payload intended to kill cancer cells after delivery, with a Drug Antibody Ratio of eight (DAR8), meaning an average of eight cancer-killing drug molecules are attached to each antibody.**	**A highly stable conjugator and cleavable linker keep the chemotherapy attached to the antibody as it travels through the bloodstream and then releases the payload only after the ADC enters the cancer cell, while still providing a strong bystander effect and**

Disclaimer. The clinical significance of data based on non-clinical studies has not been established

DEVELOPMENT HIGHLIGHTS



BG-C477 is being evaluated in a clinical development program in **patients whose tumors express CEA**, including gastrointestinal and lung cancers.

Early Phase Clinical Data

- Results of the Phase 1 study evaluating the safety, tolerability, and preliminary anti-tumor activity of BG-C477 in patients with locally advanced non-small cell lung cancer have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting.

Looking Ahead

- BeOne Medicines is advancing BG-C477 as part of its next-generation ADC portfolio with the goal of improving outcomes for patients with CEA-positive cancers. The company intends to initiate late-stage development of the molecule in the first half of 2027.